The Brightline Initiative Announces the Addition of Saudi Telecom Company - STC
The Brightline Initiative announced today that Saudi Telecom Company (STC) is joining the Brightline Initiative coalition to help advance the discipline of strategic initiative management and bridge gaps between enterprise strategy design and delivery.
This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171121005474/en/
Signature of Coalition agreement by STC Group CEO, Dr. Khaled Biyari and Brightline Executive Director Ricardo Vargas (Photo: Business Wire)
The initiative’s agreement has been signed by STC Group CEO, Dr. Khaled Biyari and by Brightline Executive Director Ricardo Vargas.
Launched early in 2017 by the Project Management Institute (PMI), the Boston Consulting Group (BCG) and the Agile Alliance, the Brightline Initiative is a non-commercial coalition dedicated to helping executives bridge the expensive and unproductive gap between strategy design and delivery.
“STC has a profound expertise and a renowned success in building and executing strategies. We are looking forward to joining a coalition that brings together leading organizations and academics worldwide to address the critical business issue of successful strategy delivery,” says STC Group CEO, Dr. Khaled Biyari. He added: “For STC, this capability is core to capturing emerging opportunities in the MENA while remaining a leader in ICT and managing overall challenges over the coming years.”
A report from a global multi-sector survey of 500 senior executives conducted by The Economist Intelligence Unit (EIU) and commissioned by the Brightline Initiative found that nearly 90% of global survey respondents admit they fail to achieve all their strategic goals because they don’t implement well, and more than half (53 percent) agree that inadequate delivery capability puts them at a competitive disadvantage.
Brightline executive director Ricardo Vargas says, “The Brightline Initiative welcomes STC to our growing ranks as we help organizations bridge the strategy implementation gap in an era of disruption and social and economic challenges. It is important to highlight that strategies are just passive plans on a piece of paper unless organizations find ways to impact employee behaviors and instill new ways of working together.”
About The Brightline Initiative
The Brightline Initiative is a coalition of leading global organizations dedicated to helping executives bridge the expensive and unproductive gap between strategy design and strategy delivery. Brightline conducts thought leadership research and promotes best practices designed to improve an organization’s ability to deliver on strategic intent.
With their headquarters in Riyadh, Saudi Telecom Group is the largest in the Middle East and North Africa based on its market value as it generated over 51,825 billion riyals (13,825 billion dollars) in realizable revenue in 2016 and 8,539 billion riyals (2,277 billion dollars) as net income. STC was established in 1998 and currently counts about 100,000,000 customers worldwide and to which they provide high-technology knowledge-based innovative solutions. It focuses on providing services to customers through a fiber-optic network that spans 137,000 kilometers across Asia, the Middle East and Europe. In Saudi Arabia (the group’s main operation site) STC operates the largest modern mobile network in the Middle East as it covers more than 99% of the country’s populated areas in addition to providing 4G mobile broadband to more than 85% of the population across the Kingdom of Saudi Arabia. Besides its main operation in Saudi Arabia, which it owns 100% of, STC’s investments include 100% ownership in Viva Bahrain, 51.8% shares in Viva Kuwait along with a management contract, 35% shares in Oger Telecom Limited in UAE and which controls Turk Telecom, Avea in Turkey, Cell-C in South Africa, 25% shares in Binariang GSM Holding in Malaysia which controls both Maxis in Malaysia and Aircel in India. In addition to the above-mentioned, STC has investments in information technology, content, distribution, contact centers and real estate, all of which support its telecom operations across the Middle East.
1] Economist Intelligence Unit (EIU), “Closing the Gap: Designing and Delivering a Strategy that Works”, 2017.
Tahirou Assane, +1 613-981-8211
Director of Operations and Program
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Incyte Announces Positive Interim Data from Phase 2 Trial of Pemigatinib, Its Selective FGFR Inhibitor, in Patients with Cholangiocarcinoma21.10.2018 10:45 | Pressemelding
Incyte Corporation (Nasdaq:INCY) announces updated data from its ongoing Phase 2 FIGHT-202 trial evaluating pemigatinib (INCB54828), its selective fibroblast growth factor receptor (FGFR) inhibitor, in patients with advanced/metastatic or surgically unresectable cholangiocarcinoma (bile duct cancer) who failed at least one previous treatment. In patients with FGFR2 translocations who were followed for at least eight months, interim study results demonstrated an overall response rate (ORR) of 40 percent, the primary endpoint, and a median progression free survival (PFS) of 9.2 months, a key secondary endpoint. These results are being presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany in a poster presentation on Sunday, October 21 from 12:45 p.m. CEST to 1:45 p.m. CEST (6:45 a.m. ET to 7:45 a.m. ET). (Location: Hall A3 – Poster Area Networking Hub; Abstract #756P) “We are pleased to share updated interim results from our ongoing FIGHT-202 trial
Servier and Taiho Oncology Announce Phase III LONSURF® Study Has Met Primary and Secondary Endpoints Demonstrating Prolonged Overall Survival and Progression-Free Survival in Patients with Refractory Metastatic Gastric Cancer21.10.2018 09:10 | Pressemelding
Servier and Taiho Oncology, Inc. (U.S.), a subsidiary of Taiho Pharmaceutical Co., Ltd. (Japan), jointly announced today clinical data from the pivotal Phase III TAS-102 Gastric Study (TAGS) evaluating LONSURF® (trifluridine/tipiracil, TAS-102) versus placebo and best supportive care in patients with heavily pre-treated metastatic gastric cancer who have progressed or are intolerant to previous lines of therapy. The study met its primary endpoint of prolonged overall survival (OS) and secondary endpoint measures of progression-free survival (PFS) consistently supported the OS results, as well as continuing to demonstrate the predictable safety and tolerability profile of trifluridine/tipiracil. Data from TAGS was presented by Dr. Hendrik-Tobias Arkenau, Executive Medical Director of the Sarah Cannon Research Institute UK and an investigator for TAGS, at the ESMO 2018 Congress in Munich, Germany during an oral session (Abstract #LBA25). The study results were simultaneously published in
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an